Alfred Sandrock
Biogen (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Multiple Sclerosis Research Studies, Polyomavirus and related diseases, Cholinesterase and Neurodegenerative Diseases, Full-Duplex Wireless Communications
Most-Cited Works
- → A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis(2006)3,309 cited
- → The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease(2016)2,998 cited
- → Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis(2000)1,507 cited
- → Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis(2006)1,330 cited
- → Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease(2022)1,255 cited
- → Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy(2012)1,222 cited
- → Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study